Global Small Molecule API Market 2022-2026

Global Small Molecule API Market 2022-2026

Technavio has been monitoring the small molecule API market and it is poised to grow by $ 71.10 bn during 2022-2026, progressing at a CAGR of 7.89% during the forecast period. Our report on the small molecule API market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by evolving small-molecule API manufacturing scenario in developing countries and the increasing number of type II drug master files. In addition, evolving small-molecule API manufacturing scenario in developing countries is anticipated to boost the growth of the market as well.

The small molecule API market analysis includes the deployment segment and geographic landscape.

Technavio's small molecule API market is segmented as below:

By Deployment

• Captive APIs
• Contract APIs

By Geographical Landscape

• North America
• Asia
• Europe
• ROW

This study identifies the growing need to focus on core competenciesas one of the prime reasons driving the small molecule API market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on small molecule API market covers the following areas:

• Small molecule API market sizing
• Small molecule API market forecast
• Small molecule API market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading small molecule API market vendors that include Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the small molecule API market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc.